Literature DB >> 7734303

Expression of sialyl-Tn in gastric cancer: correlation with known prognostic factors.

D W Miles1, J Linehan, P Smith, I Filipe.   

Abstract

Sialyl-Tn (STn) is a core region carcinoma-associated carbohydrate determinant expressed on cancer-associated mucins. Expression of STn has been associated with poor prognosis in colon and ovarian cancer, independent of other prognostic factors such as tumour grade, stage or histological type. Recent studies have suggested that STn expression may be an independent prognostic variable in gastric cancer. We have examined 158 patients with gastric cancer using the antibody B72.3 (Biomira, Edmonton, Alberta, Canada). Of these, 110 patients (70%) expressed STn. Expression of STn did not correlate with tumour differentiation or the Ming classification, but expression was noted more frequently in the relatively good prognosis intestinal type of tumours (chi 2 = 6.9, P = 0.03). Conversely, early-stage cancers showed a significantly lower frequency of expression than more advanced cases (chi 2 = 13.75, P = 0.003). In this patient group, STn expression did not influence survival, and in multivariate regression analysis only tumour stage and Lauren classification were found to be independent prognostic variables.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7734303      PMCID: PMC2033804          DOI: 10.1038/bjc.1995.207

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  17 in total

1.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.

Authors:  P LAUREN
Journal:  Acta Pathol Microbiol Scand       Date:  1965

2.  Mosaicism in the expression of tumor-associated carbohydrate antigens in human colonic and gastric cancers.

Authors:  H Nakasaki; T Mitomi; T Noto; K Ogoshi; H Hanaue; Y Tanaka; H Makuuchi; H Clausen; S Hakomori
Journal:  Cancer Res       Date:  1989-07-01       Impact factor: 12.701

3.  Gastric carcinoma. A pathobiological classification.

Authors:  S C Ming
Journal:  Cancer       Date:  1977-06       Impact factor: 6.860

4.  T N M classification for stomach cancer.

Authors:  B J Kennedy
Journal:  Cancer       Date:  1970-11       Impact factor: 6.860

5.  Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients.

Authors:  S H Itzkowitz; E J Bloom; W A Kokal; G Modin; S Hakomori; Y S Kim
Journal:  Cancer       Date:  1990-11-01       Impact factor: 6.860

Review 6.  Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives.

Authors:  S Hakomori
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

7.  Surface sialic acid reduces attachment of metastatic tumour cells to collagen type IV and fibronectin.

Authors:  J Dennis; C Waller; R Timpl; V Schirrmacher
Journal:  Nature       Date:  1982-11-18       Impact factor: 49.962

8.  Ulex europeus agglutinin I-reactive high molecular weight glycoproteins of adenocarcinoma of distal colon and rectum and their possible relationship with metastatic potential.

Authors:  T Irimura; D M Ota; K R Cleary
Journal:  Cancer Res       Date:  1987-02-01       Impact factor: 12.701

9.  Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2----6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope.

Authors:  T Kjeldsen; H Clausen; S Hirohashi; T Ogawa; H Iijima; S Hakomori
Journal:  Cancer Res       Date:  1988-04-15       Impact factor: 12.701

10.  Induction of alpha-N-acetylgalactosamine-O-serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice.

Authors:  A Singhal; M Fohn; S Hakomori
Journal:  Cancer Res       Date:  1991-03-01       Impact factor: 12.701

View more
  8 in total

1.  Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer.

Authors:  David Miles; Henri Roché; Miguel Martin; Timothy J Perren; David A Cameron; John Glaspy; David Dodwell; Joanne Parker; José Mayordomo; Alejandro Tres; James Lee Murray; Nuhad K Ibrahim
Journal:  Oncologist       Date:  2011-05-14

2.  Glycosylations versus conformational preferences of cancer associated mucin core.

Authors:  J Schuman; D Qiu; R R Koganty; B M Longenecker; A P Campbell
Journal:  Glycoconj J       Date:  2000-12       Impact factor: 2.916

Review 3.  Clinical Data on Immunotherapy in Breast Cancer.

Authors:  Julia Caroline Radosa; Lisa Stotz; Carolin Müller; Askin Canguel Kaya; Erich-Franz Solomayer; Marc Philipp Radosa
Journal:  Breast Care (Basel)       Date:  2020-10-13       Impact factor: 2.860

4.  Sialyl-Tn antigen as a useful predictor of poor prognosis in patients with advanced stomach cancer.

Authors:  S Terashima; Y Takano; T Ohori; T Kanno; T Kimura; R Motoki; T Kawaguchi
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

5.  A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer.

Authors:  D W Miles; K E Towlson; R Graham; M Reddish; B M Longenecker; J Taylor-Papadimitriou; R D Rubens
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

6.  Interactions between the breast cancer-associated MUC1 mucins and C-type lectin characterized by optical tweezers.

Authors:  Soosan Hadjialirezaei; Gianfranco Picco; Richard Beatson; Joy Burchell; Bjørn Torger Stokke; Marit Sletmoen
Journal:  PLoS One       Date:  2017-04-17       Impact factor: 3.240

7.  Sialyl-tn in cancer: (how) did we miss the target?

Authors:  Sylvain Julien; Paula A Videira; Philippe Delannoy
Journal:  Biomolecules       Date:  2012-10-11

8.  Systematic review and meta-analysis of the clinical survival significance of Sialyl-Tn expression in histological tissues from cancer patients.

Authors:  Roberto Lugo; Azalia Ávila-Nava; Rodrigo García-Pérez; Sarahí Herrera-Escalante; Jocelyne De la Cruz-Acosta; Ana Ligia Gutiérrez-Solis
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.